Gregory Hamilton - Epigenomics CEO Board
| EPGNF Stock | USD 0.50 2.00 80.00% |
CEO
Mr. Gregory Hamilton is Chief Executive Officer of Epigenomics AG since July 1, 2016. He has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. Prior to joining Epigenomics, Mr. Hamilton was Chief Executive Officer Director of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He was responsible for multiple FDAcleared products including a Human Papilloma Virus High Risk Screening assay and the first ever cleared HPV genotyping assay since 2016.
| Age | 53 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 49 30 243 450 |
| Web | https://www.epigenomics.com |
Epigenomics Management Efficiency
The company has return on total asset (ROA) of (0.245) % which means that it has lost $0.245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3802) %, meaning that it generated substantial loss on money invested by shareholders. Epigenomics' management efficiency ratios could be used to measure how well Epigenomics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CEO Age | ||
| Timothy Damadian | Fonar | 60 | |
| Ilan Danieli | Precipio | 52 | |
| Christopher Thatcher | Neuronetics | 53 | |
| Scott Hutton | BiodesixInc | 52 | |
| Harry Simeonidis | Intelligent Bio Solutions | 57 | |
| Keith Sullivan | Neuronetics | 66 | |
| Chris Thatcher | Neuronetics | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 |
Epigenomics AG Leadership Team
Elected by the shareholders, the Epigenomics' board of directors comprises two types of representatives: Epigenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Epigenomics. The board's role is to monitor Epigenomics' management team and ensure that shareholders' interests are well served. Epigenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Epigenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antje Zeise, Manager Investor Relations | ||
| Guenther Reiter, Member of the Supervisory Board | ||
| Gregory Hamilton, CEO Board | ||
| Ann Kessler, Member of the Supervisory Board | ||
| Jens Ravens, CFO Board | ||
| Heino Prondzynski, Chairman of the Supervisory Board | ||
| Helge Lubenow, Member of the Supervisory Board | ||
| Thomas Taapken, CEO, CFO and Member of Executive Board | ||
| Annett Dietrich, Manager Human Resources | ||
| Noel Doheny, CEO of Epigenomics Inc. | ||
| Andrew Lukowiak, Pres Officer | ||
| Uwe Staub, COO and Member of Executive Board | ||
| Albert Weber, Sr. VP of Fin., Accounting and Controlling | ||
| Frederic Hilke, Investor Officer | ||
| Nicola HennebergBusse, Vice President - Business Development | ||
| Jorge Garces, President Chief Scientific Officer | ||
| Nicholas Potter, Director Reimbursement and Medical Affairs | ||
| Peter Vogt, Investor & Public Relations Officer |
Epigenomics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Epigenomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 4.09 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 4.86 % | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 0.39 X | |||
| Price To Sales | 10.64 X |
Pair Trading with Epigenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Epigenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Epigenomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Epigenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Epigenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Epigenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Epigenomics AG to buy it.
The correlation of Epigenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Epigenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Epigenomics AG moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Epigenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Epigenomics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |